drugset / Trial / NCT05270863

Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia

NCT05270863

Phase 3 Completed 182 enrolled Visus Therapeutics
RandomizedCrossoverDouble-blindTreatment

Summary

Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

Timeline

Start
2022-03-30
Primary completion
2023-03-17
Completion
2023-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject BRIMOCHOL Unknown Topical
Comparator Brimonidine Small molecule Other
Comparator CARBAMOYLCHOLINE Small molecule Topical

Indications